Europeiska unionen - svenska - EMA (European Medicines Agency)

leo pharma a/s - takrolimus - dermatit, atopisk - andra dermatologiska preparat - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. inträffar fyra eller fler gånger per år) som har haft ett första svar på högst sex veckor behandling med takrolimus salva två gånger dagligen (lesioner rensas, nästan rensat eller lindrigt drabbade).

Europeiska unionen - svenska - EMA (European Medicines Agency)

astellas pharma gmbh - takrolimus - dermatit, atopisk - andra dermatologiska preparat - behandling av måttlig till svår atopisk dermatit hos vuxna som inte är tillräckligt mottagliga för eller är intoleranta mot konventionella terapier som aktuella kortikosteroider. behandling av måttlig till svår atopisk dermatit hos barn (2 år och äldre) som misslyckades med att svara adekvat på konventionella terapier såsom topikala kortikosteroider. underhåll behandling av måttlig till svår atopisk dermatit för förebyggande av facklor och en förlängning av flare-gratis intervaller i patienter upplever en hög frekvens av sjukdomar exacerbationer (jag. förekommer 4 eller fler gånger per år) som har fått ett första svar på högst 6 veckor behandling av två gånger dagligen takrolimussalva (skador avlägsnas, nästan rensade eller mildt drabbade).

Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter för dermatit, med undantag av kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatit, atopisk - andra dermatologiska preparat - staquis är indicerat för behandling av mild till måttlig atopisk dermatit hos vuxna och pediatriska patienter från 2 års ålder ≤ 40% av kroppsytan (bsa) som påverkas.

Europeiska unionen - svenska - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatit, atopisk - andra dermatologiska preparat - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatit, atopisk - andra dermatologiska preparat - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatit, atopisk - andra dermatologiska preparat - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mimer medical - estradiolhemihydrat - transdermal spray, lösning - 1,53 mg/sprayning - etanol, vattenfri hjälpämne; estradiolhemihydrat 1,58 mg aktiv substans - Östradiol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

mimer medical - estradiolhemihydrat - transdermal spray, lösning - 1,53 mg/sprayning - etanol, vattenfri hjälpämne; estradiolhemihydrat 1,58 mg aktiv substans - Östradiol

Europeiska unionen - svenska - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinibmaleat - agenter för dermatit, med undantag av kortikosteroider - hundar - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.